Beam Therapeutics (BEAM) Share-based Compensation (2019 - 2026)

Beam Therapeutics (BEAM) has reported Share-based Compensation for 8 consecutive years, with $19.0 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Share-based Compensation fell 28.63% year-over-year to $19.0 million; the TTM figure through Mar 2026 stood at $96.4 million (down 18.16% YoY), while the FY2025 annual figure was $94.2 million, down 21.89% from the prior year.
• Share-based Compensation retreated to $19.0 million in Q1 2026 per BEAM's latest filing, from $20.4 million in the prior quarter.
• Across five years, Share-based Compensation topped out at $97.6 million in Q3 2024 and bottomed at $18.0 million in Q1 2022.
• Historically, Share-based Compensation has averaged $37.9 million across 5 years, with a median of $26.3 million in 2023.
• Annual changes were most pronounced in 2022 — Share-based Compensation soared 288.02% — and 2023, when it tumbled 53.31%.
• Beam Therapeutics' Share-based Compensation stood at $48.4 million in 2022, then sank by 53.31% to $22.6 million in 2023, then jumped by 33.61% to $30.2 million in 2024, then slumped by 32.33% to $20.4 million in 2025, then retreated by 6.87% to $19.0 million in 2026.
• Business Quant data shows BEAM's Share-based Compensation at $19.0 million in Q1 2026, $20.4 million in Q4 2025, and $84.2 million in Q3 2025.